Compare Costco Wholesale Corporation (COST) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Gilead Sciences, Inc. — how do they compare? Costco Wholesale Corporation trades at $919.57 (market cap $408.78B), while Gilead Sciences, Inc. trades at $131.97 (market cap $161.45B). The key difference: Costco Wholesale Corporation is far larger — about 2.5× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.52%). Which is the better fit depends on your goals.
| COST | GILD | |
|---|---|---|
Market Cap | $408.78B | $161.45B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $155.80 |
52-Week Low | $849.63 | $108.22 |
Enterprise Value | $396.92B | $175.98B |
Dividend Yield | 0.64% | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $921.73, down 0.51% on the day, with a bearish technical signal but strong fundamental growth. Revenue reached $275.24B in 2025 with net income of $8.10B, and March 2026 sales grew 11.3% year-over-year. The stock carries premium valuations (P/E 46.37, P/S 1.4) while maintaining steady margin expansion. Analyst consensus remains strongly bullish with a $1,120 price target, though recent earnings miss in Q1 2026 highlights execution risks amid high expectations.
Outlook: Costco's membership fee increase and warehouse expansion support long-term growth, but elevated valuation requires flawless execution. Risks include competitive pressures and macroeconomic sensitivity. Institutional accumulation continues, with 65% analyst buy ratings signaling confidence in the company's resilient business model and cash flow generation.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
